M802 / YZY Biopharma - LARVOL DELTA

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Wuhan YZY Biopharma Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Breast Cancer • HER2 Positive Breast Cancer • Solid Tumor • CA 19-9 • CA724

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Wuhan YZY Biopharma Co., Ltd.; Trial completion date: Mar 2021 ➔ Dec 2023; Trial primary completion date: Dec 2020 ➔ Nov 2023

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • CA 72-4 • Cancer antigen 19-9 • CEACAM5 • MUC16